| Systematic (IUPAC) name | |
|---|---|
| (11β)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3,20-dioxopregna-1,4-dien-21-yl propionate | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a604021 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Topical |
| Identifiers | |
| CAS number | 73771-04-7 |
| ATC code | D07AC18 |
| PubChem | CID 6714002 |
| DrugBank | DB01130 |
| ChemSpider | 47402 |
| UNII | V901LV1K7D |
| ChEMBL | CHEMBL1200386 |
| Synonyms | [2-[(8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate |
| Chemical data | |
| Formula | C27H36O8 |
| Mol. mass | 488.57 g/mol |
| |
|
Prednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. Compared to other topical corticosteroids, like betamethasone, repeated prednicarbate use does not cause skin atrophy as quickly.[citation needed] Corticosteroids have always been an important part of the pharmacological arsenal of dermatology; however, their tendency to produce side-effects has caused the need to search for new preparations.
It is nonhalogenated.[1]
|
||||||||||||||||||||||||||||||||
| This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)